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Abstract
Background: Except for early T1,2 N0 stages, the prognosis for patients with oral cavity cancer (OCC) is reported to be worse
than for carcinoma in other sites of the head and neck (HNC). The aim of this work was to assess disease outcome in OCC
following IMRT.
Between January 2002 and January 2007, 346 HNC patients have been treated with curative intensity modulated radiation
therapy (IMRT) at the Department of Radiation Oncology, University Hospital Zurich. Fifty eight of these (16%) were referred
for postoperative (28) or definitive (30) radiation therapy of OCC.
40 of the 58 OCC patients (69%) presented with locally advanced T3/4 or recurred lesions. Doses between 60 and 70 Gy were
applied, combined with simultaneous cisplatin based chemotherapy in 78%. Outcome analyses were performed using Kaplan
Meier curves.
In addition, comparisons were performed between this IMRT OCC cohort and historic in-house cohorts of 33 conventionally
irradiated (3DCRT) and 30 surgery only patients treated over the last 10 years.
Results: OCC patients treated with postoperative IMRT showed the highest local control (LC) rate of all assessed treatment
sequence subgroups (92% LC at 2 years). Historic postoperative 3DCRT patients and patients treated with surgery alone
reached LC rates of ~70–80%. Definitively irradiated patients revealed poorest LC rates with ~30 and 40% following 3DCRT
and IMRT, respectively.
T1 stage resulted in an expectedly significantly higher LC rate (95%, n = 19, p < 0.05) than T2-4 and recurred stages (LC ~50–
60%, n = 102).
Analyses according to the diagnosis revealed significantly lower LC in OCC following definitive IMRT than that in pharyngeal
tumors treated with definitive IMRT in the same time period (43% vs 82% at 2 years, p < 0.0001), while the LC rate of OCC
following postoperative IMRT was as high as in pharyngeal tumors treated with postoperative IMRT (>90% at 2 years).
Conclusion: Postoperative IMRT of OCC resulted in the highest local control rate of the assessed treatment subgroups. In
conclusion, generous indication for IMRT following surgical treatment is recommended in OCC cases with unfavourable features
like tight surgical margin, nodal involvement, primary tumor stage >T1N0, or already recurred disease, respectively.
Loco-regional outcome of OCC following definitive IMRT remained unsatisfactory, comparable to that following definitive 
3DCRT.
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Background
Except for early T1,2 N0 stages, the prognosis for patients
with OCC seems to be worse than for carcinoma in other
sites of the head and neck (HNC). Many different treat-
ment approaches have been tested over the last two dec-
ades [1-23] (interstitial brachytherapy with its excellent
results in early stage T1,2 tumors of the mobile tongue or
floor of the mouth is not listed, as this does not fall in the
category of the patient sample focussed here). In operable
patients, adjuvant as well as so called 'neo-adjuvant' con-
cepts have been employed, using several radio-therapeutic
schedules in combination with different chemotherapeu-
tic drugs prior to or following surgery. However, loco-
regional control in T3,4 and recurrent stages remains
unfavourable. In contrast to pharyngeal and laryngeal
tumors, loco-regional outcome in OCC is worse when
using definitive radio(-chemo)therapy alone.
Loco-regional disease control has a dominant impact on
survival, as distant control rates as high as ~90–95 % at 5
years are reported [24].
Intensity modulated radiation therapy (IMRT) technique
represents a novel treatment option with a potential
capacity for better loco-regional control in inoperable dis-
ease. Improved loco-regional outcome following IMRT
has been reported for nasopharyngeal [25-28] and
oropharyngeal tumors [22,29,30]. Also in hypopharyn-
geal tumors, a tendency towards better outcome has been
described [31]. Published IMRT results related to OCC are
confined to two published articles: a series of 27 patients
[22], and 29 patients [23], both including mostly postop-
erative IMRT patients, with resulting 2-year loco-regional
control rates of 59% and 78%, respectively. Both authors
found a significantly worse LC rate in OCC compared
with oropharyngeal tumors.
To assess disease outcome of OCC following IMRT, we
analysed 58 consecutively irradiated OCC patients. In
addition, a comparison between the IMRT cohort and our
historic OCC cohorts treated with (1) surgery alone, (2)
definitive three-dimensional conformal radiation therapy
(3DCRT), and (3) postoperative 3DCRT was performed.
Results
Disease control of the entire OCC cohort
Figure 1 shows survival rates of 121 assessed OCC patients
treated over the last 10 years (see also Table 1). Eighty %
of all loco-regional events have been observed during the
first 12 months following treatment.
Outcome according to the treatment modality
The highest LC rate was achieved in patients treated with
combined surgery and postoperative IMRT (n = 28, 2-year
LC 92%), whereas postoperative 3DCRT (n = 20) and sur-
gery alone (n = 30) resulted in LC rates of ~80%. Defini-
tive radiation reached 2-year LC rates of ~30% following
3DCRT (n = 20) and 43% following IMRT technique (n =
30, p < 0.0005), respectively.
Patients who presented with a recurrence following sur-
gery alone have been analysed separately, as recurrence is
characterized by a poor prognosis, with ~30% LC at 2
years.
Outcome according to the T-stage
In T1 tumors, a high 2-year LC of 95% (n = 19/121, 13 of
them treated with surgery alone, p < 0.05) was found,
whereas the LC of T2-4 and recurred tumors showed infe-
rior control rates (~50–60% at 2 years, Figure 2). LC in T1-
2 N0-2b stages was found superior to T3-4 N2c and
recurred tumors (80 vs 60%, p = 0.01).
In the surgery alone subgroup there were 4 local failures
in 14 T1/2 N0 stages (~1/3), one of them with simultane-
ous nodal relapse, and another two with nodal failure
alone (= 6/14 patients with loco-regional failure). When
last time seen, four of these 6 patients were alive with no
evidence of disease after salvage treatment, two of them
were alive with disease.
Outcome of the IMRT subgroup
The postoperative IMRT subgroup (n = 28) reached 2-year
local, nodal, distant control rates of 92, 91, 95%, and dis-
ease free and overall survival rates of 87 and 83%, respec-
tively. In the definitive IMRT subgroup (n = 30), the
corresponding survival rates were substantially lower with
43, 86, 85, 40, and 30%.
Local (LC), nodal (NC), distant control (DC), overall survival  (OAS), and disease free survival (DFS) of the entire analysed  oral cancer cavity cohort (N = 121 patients) Figure 1
Local (LC), nodal (NC), distant control (DC), overall survival 
(OAS), and disease free survival (DFS) of the entire analysed 
oral cancer cavity cohort (N = 121 patients).
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Outcome of OCC vs pharyngeal tumors treated with IMRT
Comparisons of LC rates in OCC following postoperative
IMRT (n = 28) vs that in squamous cell carcinoma of the
oropharynx, hypopharynx, and larynx treated in the same
time period (January 2002 to January 2007, n = 42) did
not show any significant difference (>90% 2-y LC, p =
0.29, Figure 3), whereas in definitively IMRT irradiated
OCC patients (n = 30), LC was significantly worse with
43% vs 82% in definitively irradiated pharyngeal tumors
(n = 174, p < 0.0001, Figure 4), despite of a similar volu-
metric tumor load in these two groups, with total gross
tumor volumes of mean/median 45/41 cc in OCC (range
9–123 cc) vs 46/39 cc in pharyngeal tumors (range 1–170
cc).
Postoperative IMRT: identically high local control rates in 28  oral cavity cancer patients and 42 patients treated for a squa- mous cell carcinoma located in the pharynx (nasopharyngeal  tumors excluded) Figure 3
Postoperative IMRT: identically high local control rates in 28 
oral cavity cancer patients and 42 patients treated for a squa-
mous cell carcinoma located in the pharynx (nasopharyngeal 
tumors excluded).
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Table 1: Patient and disease characteristics in oral cavity cancer (OCC, N = 121)
Factors definitive IMRT postop IMRT definitive 3D-CRT postop 3D-CRT Surgery alone N total
N3 0 2 8 1 3 2 0 3 0 1 2 1
Time interval 10/02 – 1/07 11/02 – 1/07 5/96 – 2/04 04/00 – 3/03 5/96 – 8/05 5/96 – 5/06
gender (m:f) 2 : 1 2 : 1 ~2 : 1 2 : 1 4 : 1
mean age (years) 61 61 62 60 58 ~60
T stages T1 0 4 0 2 13 19
T2 6 8 1 5 12 32
T3 3 1 3 1 0 8
T4 12 8 3 10 5 38
recurrence 9 7 6 2 0 24
N stages N0 9 7 2 6 19 43
N1 4 4 4 6 7 25
N2a/b 2 12 2 5 2 23
N2c 13 4 1 1 2 21
N3 1 0 0 0 0 1
UICC stages l0 0 0 0 1 1 11
ll 0 2 0 2 7 11
lll 0 4 5 4 5 18
lVA 20 15 8 14 7 64
lVB 1 0 0 0 0 1
recurrence 9 7 0 0 0 16
concomitant CT 21/30 24/28 3 0 0 48
mean/median FU (mo)
(range)
16/12
(3–57)
20/19
(4–60)
30/19
(7–96)
40/41
(8–84)
58/48
(16–126)
FU: follow up; CT: chemotherapy; mo: months
Local control rates of all patients, analysed according to the  T-stages Figure 2
Local control rates of all patients, analysed according to the 
T-stages. T1 staged tumors showed a superior local outcome 
(p = 0.045), while all other stages including recurrences, did 
not differ.Radiation Oncology 2007, 2:16 http://www.ro-journal.com/content/2/1/16
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Treatment tolerance of IMRT in OCC
IMRT was well tolerated with respect to early toxicity as
well as late effects. 14 out of 58 patients needed a tempo-
rary gastric feeding tube. No radiation interruption
occurred due to treatment related effects. No late xerosto-
mia grade 3 has been observed, and none of these patients
at risk for mandible bone necrosis developed a radio-
osteonecrosis [32].
Discussion
The purpose of the current study was to analyse loco-
regional disease outcome of OCC following IMRT, related
to the outcome of own historic OCC cohorts, in order to
assess the value of IMRT in OCC.
The limits of this study are the small size of compared
samples, the retrospective character and different treat-
ment intervals and follow up periods of the historic con-
trols, respectively. The different treatment approach with
respect to the systemic therapy may, in addition, influence
the outcome.
However, the IMRT subgroup data were prospectively
assessed and represent the largest OCC IMRT population
reported so far.
T1 stage (mainly surgically treated) could be confirmed as
a statistically significant favourable outcome predictor. In
intermediate and advanced stages, loco-regional control
after radiation alone (+/- chemotherapy) is unsatisfactory,
and IMRT technique does not seem to have an impact on
this fact. Patients with loco-regionally extended disease
are often candidates for primary radiation – the definitive
radiation group represents per se an unfavourable selec-
tion (Table 1); however, in pharyngeal tumors character-
ized by this same condition, primary radiation is able to
reach much higher LC rates, sometimes even approximat-
ing those of surgical cohorts. The reason for this difference
between OCC and other HNC entities remains specula-
tive; biological differences may likely represent a relevant
factor. However, the excellent results following interstitial
brachytherapy for early T1,2 N0 stages with LC rates >
80% [2,33,34] prove radiation is basically highly effective
in this entity as well, at least for small tumor volumes.
Our T1,2 N0 surgery alone cohort developed loco-
regional failure in nearly half the cases, however the sam-
ple size is too small to allow to draw reliable conclusions.
Surgery combined with postoperative IMRT +/- chemo-
therapy achieved high loco-regional control rates, also in
tumors with intermediate or loco-regionally advanced
stages. This observation may be the key information of the
current analysis. In addition, postoperative IMRT showed
a tendency towards better local control than postoperative
3DCRT, however the sample sizes are small, and this
observation needs to be confirmed based on larger sample
sizes and longer follow up.
Comparison of the presented OCC results with published
data [1-23] is difficult, as too many different factors (like
treatment sequence, stage, combined modalities, sample
sizes, outcome parameters) confound the results.
To our knowledge two other articles on IMRT in OCC
[22,23] are available to date. Eisbruch et al [22] found
identical LC rates in postoperative vs definitive IMRT
patients, with a significantly better 3-year loco-regional
control in oropharyngeal tumors than in the other HNC
sub-sites (94% for 80 oropharynx, 75 and 60% for 12
hypopharyngeal and 11 laryngeal tumor patients, and
59% in 27 mostly operated OCC patients, respectively).
Similarly, Yao et al [23] observed identical postoperative
and definitive IMRT results with respect to LC, and a sig-
nificantly higher LC rate for their mostly definitively irra-
diated oropharyngeal tumors (98% 2-y LC vs 78% for
mostly operated OCC).
Conclusion
The following conclusions can be drawn from the pre-
sented data:
- Combined treatment with surgery and postoperative
(chemo-)IMRT resulted in a high control rate of >90% in
OCC >T1N0, comparable to the favourable results in
other advanced HNC entities treated with IMRT +/-sur-
gery.
Definitive IMRT: significantly different local control rates in  favour to 174 patients treated for squamous cell carcinoma  of the pharynx (nasopharyngeal tumors excluded) vs 30 oral  cavity cancer (OCC) patients (p < 0.0001) – despite of an  identical tumor volume load in the two groups, with mean/ median 45/41 cc and 46/39 cc Figure 4
Definitive IMRT: significantly different local control rates in 
favour to 174 patients treated for squamous cell carcinoma 
of the pharynx (nasopharyngeal tumors excluded) vs 30 oral 
cavity cancer (OCC) patients (p < 0.0001) – despite of an 
identical tumor volume load in the two groups, with mean/
median 45/41 cc and 46/39 cc.Radiation Oncology 2007, 2:16 http://www.ro-journal.com/content/2/1/16
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- LC in OCC following definitive IMRT was substantially
lower than following postoperative IMRT
- LC in OCC following definitive IMRT was substantially
lower than that observed in definitively IMRT-treated pha-
ryngeal tumors with comparable tumor load
- IMRT seems not to improve the unsatisfactory loco-
regional outcome in definitively irradiated OCC com-
pared to patients treated with 3DCRT techniques
These findings are, in consequence, suggestive for a com-
bined approach with surgery followed by postoperative
IMRT may represent the treatment of choice in OCC >T1
N0. An additional reason for favouring a sooner applica-
tion of postoperative IMRT is the improved tolerance pro-
file such as substantially reduced xerostomia
[22,26,35,36] and a minimized risk for radio-osteonecro-
sis [32] following IMRT.
Methods
Patients
In Table 1, patient and disease characteristics of the entire
OCC patient cohort treated over the last decade (5/1996-
1/2007) are displayed.
Approximately half the patients presented with a floor of
the mouth carcinoma, one third with a tongue/floor of
the mouth cancer, 10% with a tumor of the gingival/man-
dible. The remaining 10% consisted of tumors of the
tongue or upper jaw.
Assessed subgroups
a) IMRT patients
Fifty eight consecutive patients with OCC were irradiated
with IMRT at the Department of Radiation Oncology,
University Hospital Zurich, between October 2002 and
January 2007. 40/58 patients presented with locally
advanced T4/3 or recurred disease. Thirty patients (52%)
underwent definitive radiation therapy. In 78% of all,
simultaneous cisplatin chemotherapy was given.
b) 3DCRT controls
Thirty four control patients treated with 3DCRT in the
time interval between May 1996 and March 2003 (prior to
the clinical implementation of IMRT and the inclusion of
all HNC patients in our IMRT program, respectively), were
retrospectively assessed for comparative purposes (Table
1). This subgroup was comparable with the IMRT sub-
group in terms of T-stages (75% T3,4 or recurred tumors),
definitively irradiated patients (~50%), age (~60 y) and
gender (2:1), respectively.
c) Surgical controls
In addition, 30 consecutive patients who were treated
with surgery alone between May 1996 and August 2005,
were retrospectively assessed for comparative purposes
(Table 1). The percentage of locally advanced T3,4 or
recurred cases was expectedly low with 17% (nine patients
presented with stage T1N0, 5 with T2N0).
IMRT Planning systems
Volume delineation, dose calculation and plan optimiza-
tion was performed on a Varian Treatment Planning Sys-
tem (Eclipse®, Version 7.3.10, Varian Medical Systems,
Hansen Way, Palo Alto CA, 94304-1129).
Chemotherapy
Simultaneous chemotherapy was given in most (78%) of
the IMRT patients. In the postoperative situation this was
not the standard treatment until approximately 2000 [37-
39]. Since then, all definitive as well as postoperative
patients with no specific contraindications undergo com-
bined simultaneous cisplatin chemotherapy (40 mg/m2,
1x/radiation week) at our institution.
Irradiation
General indications for postoperative radiation in oper-
ated patients were locally advanced stages, positive surgi-
cal margins, involvement of 2 or more lymph nodes, or
extra-capsular extension, respectively.
-IMRT was delivered by 6 MV photon beams on a Varian
linear accelerator with sliding window technique. The
technical solution of choice was a 5 field arrangement
('class solution') for all patients. 70 Gy in 33 sessions was
given for definitive IMRT. IMRT treatment was delivered
using simultaneously integrated boost (SIB) technique;
details on SIB are reported elsewhere [36]. The dose in
electively irradiated regions was 54 Gy/33 fractions (range
50–56).
The high dose planning target volume (PTV1): included
the gross tumor volume (GTV) and a margin of approxi-
mately 1.5 cm. Elective irradiation of lymphatic regions in
T3,4 or N1 situations included level I,II,III and lV bilater-
ally of the neck and level 5 on the ipsilateral side. In
patients with N1, the retropharyngeal nodes bilaterally
were also included. On the uninvolved side of the neck,
the upper field border was at the lower border of the trans-
verse process of C1.
Patient alignment was checked before each irradiation by
portal imaging; deviations of >3 mm were corrected
before treatment.
-3DCRT  treatment has been delivered by 6MV photon
beams on the same Varian linear accelerator, using stand-Radiation Oncology 2007, 2:16 http://www.ro-journal.com/content/2/1/16
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ard techniques as described in G Fletcher 1980/WM
Mendenhall 1994 (Textbooks).
Definitive 3DCRT has been delivered using accelerated
schedules with concomitant boost or standard fractiona-
tion with 2.0 Gy per fraction, 6 fractions/week, respec-
tively.
Total treatment doses ranged between 68 and 74 Gy in
definitive 3DCRT, and between 60 and 66 Gy in postop-
erative patients, for IMRT as well as 3DCRT techniques,
respectively.
Statistics
All our statistical analyses consisted of comparing groups
according to a time-to-event endpoint (survival analysis),
using Kaplan-Meier curves and log-rank tests imple-
mented in StatView® (Version 4.5). P values < 0.05 were
considered as significant.
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